.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Teva
Chinese Patent Office
Cipla
Accenture
UBS
Argus Health
Express Scripts
Harvard Business School

Generated: June 25, 2017

DrugPatentWatch Database Preview

LASTACAFT Drug Profile

« Back to Dashboard

What is the patent landscape for Lastacaft, and what generic Lastacaft alternatives are available?

Lastacaft is a drug marketed by Allergan and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-six patent family members in twenty-eight countries.

The generic ingredient in LASTACAFT is alcaftadine. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the alcaftadine profile page.

Summary for Tradename: LASTACAFT

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list27
Clinical Trials: see list5
Patent Applications: see list34
Drug Prices:see details
DailyMed Link:LASTACAFT at DailyMed

Pharmacology for Tradename: LASTACAFT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 2010RXYesYes8,664,215► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LASTACAFT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 20105,468,743► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LASTACAFT

Drugname Dosage Strength RLD Submissiondate
alcaftadineOphthalmic Solution0.25%Lastacaft7/30/2014

International Patent Family for Tradename: LASTACAFT

Country Document Number Estimated Expiration
EcuadorSP088786► Subscribe
Ukraine94938► Subscribe
Denmark2004196► Subscribe
Norway20084593► Subscribe
Taiwan200815016► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Express Scripts
US Army
UBS
McKesson
Covington
Deloitte
Federal Trade Commission
Fish and Richardson
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot